1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Decentralised European approval for Shire's Vyvanse for ADHD

 
• By Pial Ganguli

Shire has received European approval of Vyvanse (lisdexamfetamine dimesylate, to be known as Elvanse, or Tyvense in Ireland) for attention deficit/hyperactivity disorder (ADHD) via the decentralised procedure.

Shire has received European approval of Vyvanse (lisdexamfetamine dimesylate, to be known as Elvanse, or Tyvense in Ireland) for attention deficit/hyperactivity disorder (ADHD) via the decentralised procedure.

The drug is now indicated for use as part of a comprehensive treatment program for ADHD in children aged 6...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

More from Therapeutic Category